About Juvena
- Juvena Therapeutics is a venture-backed biotechnology company unlocking the therapeutic potential of stem cell-secreted proteins and accelerating their development into life-saving therapeutics for chronic and age-related diseases.
- We are achieving this through an Artificial Intelligence-enabled platform that combines a compounding database mapping secreted proteins to specific disease phenotypes, an in silico screening technology, wetlab screening in primary human cell and animal models, and protein engineering capabilities.
- Our goal is to use this integrated platform to accelerate the development of regenerative biologics.
Meet the Team
We’ve brought together a team of brilliant minds to unlock the brilliance of the human body.
Join Our Team
Be part of the team that’s decoding secreted proteins to improve human health
Recent News
January 24, 2024
Juvena Therapeutics Receives FDA Orphan Drug Designation for JUV-161 for the Treatment of Myotonic Dystrophy Type 1
Read More »August 30, 2023
CEO Dr. Hanadie Yousef is recognized by Business Insider on their shortlist of 30 under 40 Transforming Healthcare
Read More »May 26, 2023
Endpoints: CEO and co-Founder Dr. Hanadie Yousef is recognized by Endpoints for her lifelong scientific work and discoveries, for her entrepreneurship and business leadership as part of the 2023 “20 under 40” list of exceptional biotech leaders and global change makers
Read More »May 19, 2023
Juvena’s CEO and co-founder, Dr. Hanadie Yousef, was named among a distinguished short list of Emerging Pharma Leaders by Pharmaceutical Executive, which highlights her personal story and what drives Dr. Yousef’s passion for decoding secreted proteins for better human health
Read More »November 8, 2022
